

13 October 2016

EVE Investments Webcast on Omniblend Innovation

EVE Investments (ASX:EVE), has released a webcast of Investment Director, Mr Ben Rohr and Omniblend Innovation Managing Director, Mr Arie Nudel, discussing the Omniblend Innovation business in particular Faulding™ GlucoControl™.

To view the video please visit the EVE Investments website, www.eveinvestments.com.au

-ENDS-

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments

About Omniblend Innovation

Omniblend Innovation is a private Melbourne based company developing evidence-based dietary interventions to improve the lives of people with common chronic diseases such type-2 diabetes and low blood pressure (hypotension).

In August 2016 the Company launched its maiden product, Faulding® GlucoControl™ for use in the dietary management of type 2 diabetes and pre-diabetes.

For more information, please visit www.obinnovation.com.au

For more information:

Bill Fry
Executive Director
+61 8 6465 5500
billf@eveinvestments.com.au